Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

Researcher comment: Positive OS data for osimertinib in FLAURA trial | Suresh RamalingamПодробнее

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLCПодробнее

Suresh Ramalingam: Osimertinib vs comparator EGFR-TKI 1st-line in EGFRm advanced NSCLC (FLAURA)Подробнее

Dr. Suresh Ramalingam Reviews the GALAXY-1 Trial ResultsПодробнее

Final overall survival (OS) data from FLAURA trialПодробнее

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patientsПодробнее

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLCПодробнее

FLAURA final analysis: osimertinib for first-line EGFRm NSCLCПодробнее

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

Dr. Ramalingam Discusses the Results of the Phase III REVEL Study in NSCLCПодробнее

#WCLC19 Thought Leader Interview: Dr. Suresh RamalingamПодробнее

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLCПодробнее

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)Подробнее

Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLCПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLCПодробнее

The FLAURA Trial in EGFR+ NSCLCПодробнее

Eagerly anticipated results of the FLAURA trialПодробнее